Thin
1 / 2
Semaglutide is a GLP-1 receptor agonist that regulates blood glucose by stimulating insulin secretion and inhibiting glucagon release. It is commonly used in clinical research for type 2 diabetes management, weight management, and obesity-related studies.
Semaglutide (marketed as Wegovy®/Ozempic®) is administered by once‑weekly subcutaneous injection. Common dosing protocols for obesity and weight management range from 0.25 mg up to 2.4 mg weekly, with gradual titration based on tolerance and therapeutic goals. A new higher 7.2 mg weekly dose has been approved in some regions to enhance weight‑loss efficacy in clinical settings.
Semaglutide is protected by a broad patent portfolio covering compositions, formulations, and therapeutic uses. Key U.S. patents include:
These extended protections help delay generic competition in major markets such as the U.S. until the late 2030s–early 2040s.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the natural hormone GLP-1 to help individuals manage their weight and improve metabolic health.
It regulates appetite and blood sugar levels by stimulating insulin secretion and inhibiting glucagon release.
It is administered via a once-weekly subcutaneous injection, with doses usually gradually titrated based on tolerance.
Common dosing ranges from 0.25 mg up to 2.4 mg weekly. In some regions, a higher 7.2 mg weekly dose has been approved to enhance weight-loss efficacy.
Due to a broad patent portfolio protecting its compositions and formulations, generic competition in major markets like the U.S. is expected to be delayed until the late 2030s to early 2040s.
